2023 World Conference on Lung Cancer (Posters)-EP11.03. Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody

EP11.03. Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody - PDF(Slides)

Back to course

Pdf Summary

A retrospective study was conducted to investigate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC) who had previously received anti-programmed death-1 (PD-1) and/or anti-programmed death ligand-1 (PD-L1) antibodies. The study included 23 patients who received nivolumab/ipilimumab therapy after previous immunotherapy. The objective response rate (ORR) was 17%, with a disease control rate (DCR) of 48%. The highest grade of immune-related adverse events (irAEs) was grade 3, occurring in 11% of cases. These results suggest that re-immunotherapy with nivolumab plus ipilimumab may be feasible and provide clinical benefit in selected patients.<br /><br />Previous retrospective studies have shown limited efficacy of PD-(L)1-targeted re-immunotherapy after anti-PD-(L)1 therapy. However, in this study, the response to nivolumab plus ipilimumab therapy appears to be superior to previous studies. The incidence of severe irAEs with nivolumab/ipilimumab was lower compared to previous immunotherapies, although 30% of patients had to discontinue therapy due to irAEs. The study concludes that re-immunotherapy with anti-PD-1 and anti-CTLA-4 antibodies may be beneficial, but further studies are needed to identify the patient population that would benefit the most.<br /><br />The study included patients with NSCLC who had advanced stage, unresectable disease, or postoperative recurrence. The best response to nivolumab/ipilimumab immunotherapy was equal or inferior to that of the prior immunotherapy. The study also found that re-immunotherapy with anti-CTLA-4 antibody may not be effective unless the prior immunotherapy with anti-PD-(L)1 antibody was effective. Although most irAEs were not severe, physicians need to carefully select patients for re-immunotherapy.<br /><br />In summary, re-immunotherapy with nivolumab plus ipilimumab after anti-PD-1 and/or anti-PD-L1 immunotherapy had a higher ORR than previous studies. The study suggests that this re-immunotherapy regimen may be feasible and provide clinical benefit, but further prospective studies are required to determine the optimal patient population for this treatment approach.

Asset Subtitle

Zentaro Saito

Meta Tag

Speaker Zentaro Saito

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

efficacy

safety

re-immunotherapy

nivolumab

ipilimumab

non-small cell lung cancer

NSCLC

anti-PD-1

anti-PD-L1